Effect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome.

Abstract

Although current evidence suggests that initial dose of 200mg/kg poractant alfa reduces mortality in the treatment of respiratory distress syndrome (RDS), these data were obtained in a highly heterogeneous group of patients and neither of them addressed mortality as primary outcome. The aim of this study was to investigate the effects of poractant alfa and beractant on mortality when administered as early rescue surfactant therapy in very preterm infants. We retrospectively evaluated preterm infants followed in our unit between May 2017 and November 2018 whose gestational age (GA) was ≤28weeks and received surfactant within the first 2hours of life. Morbidities and mortality rates were compared between infants who received initial doses of 200mg/kg poractant alfa and 100mg/kg beractant. Data from 200 infants who met the inclusion criteria were analyzed. There were 112 patients in the poractant alfa group and 88 patients in beractant group. Mean gestational age in these groups was 26±2 and 25.8±1.8weeks (P=0.45) and mean birth weight was 812±243 and 840±208g (P=0.39), respectively. The poractant alfa and beractant groups had similar rates of overall mortality (53.5% vs 56.8%), mortality in first 7days (30.5% vs 25.8%), and beyond day 7 (16.4% vs 13.3%) (P>0.05). There were no differences in the incidence of preterm morbidities among the two groups. We were unable to demonstrate the superiority of poractant in terms of mortality in very preterm infants with RDS. These findings need to be supported by multicenter, randomized controlled trials.